about
Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosisEfficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.Gene and cell-based therapy for diabetes mellitus: endocrine gene therapeutics.Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitusGenetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography.Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.Novel hormonal delivery method using the ink-jet technology: application to pulmonary insulin therapies.Epigenetics: Reprogrammable interface of the genome and environments.Differentiation-induced insulin secretion from nonendocrine cells with engineered human proinsulin cDNA.Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.High-throughput screening of small interfering ribonucleic acid identifies important modulators in islet dysfunction and apoptosis.Temporal and Spatial Cellular Distribution of Neural Crest Derivatives and Alpha Cells during Islet DevelopmentIn vitro and pathological investigations of MODY5 with the R276X-HNF1beta (TCF2) mutation.PPARgamma2 pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients.Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label,Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.Sarcopenia, frailty circle, and treatment with SGLT2 inhibitorsPharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.Preferential transmission of maternal allele with DQA1*0301-DQB1*0302 haplotype to affected offspring in families with type 1 diabetesCorrigendumSodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus)
P50
Q28586557-67B47CD9-0BE3-4541-BD37-BE38FFAEB44AQ31064304-767EA651-8D9D-4A6E-85DB-CE0AA3AD466CQ35176455-D8E337B3-698D-49D9-8B49-8A5BD07EB5A4Q35558413-E7073983-5A4C-49E5-8D91-BE5589183E2AQ35666237-B12632BF-D017-4D4B-A113-DB398D3F6A19Q35879325-D3049EA0-89CB-4283-95B2-E333AABE051EQ36092155-3ACD2FC7-BFEA-4E30-85DE-585AF3684AD7Q37653114-3A5008A0-9DEB-4361-A1D8-BB9BEA827D88Q38433504-3F94C87C-CEB8-4B01-9BF9-1FC2B88768A2Q38434957-9DD32399-81C3-4AB4-8A65-39FE43C50F81Q39575939-D28668A8-0005-442C-BFEC-F85C7E868C67Q39678883-A351E345-A4D9-4165-B1C1-6BF42B662C72Q40918274-8D26D5AD-0592-49FE-B51A-48EC125C094AQ41234175-7500CF22-BD76-4B88-8EBD-02018FC43CF8Q41819534-9EE5F412-2561-4775-A6F4-7E813FBEB6B6Q42002486-DB2FFEE1-2382-48CB-B9BD-67C285CDEF7AQ42518996-60FB4DF2-0A1C-4E46-A94D-0823E0EE001DQ43940848-DB833258-32A4-40CF-A5EC-285A4839CA09Q48147721-D4B16334-2435-4A5E-AC0B-CE44B0BF9475Q49963630-30D19A0F-4C09-4334-9447-0D7569D2E48CQ51291594-5B3DBF10-8ADB-455E-8E4E-B044830B7B0EQ51324403-4E729D5E-F6A5-4CC6-9D07-3E0436C3574DQ58111293-12FB5063-85C5-47DC-8A97-95F8712875A4Q64976338-849D51C7-AA44-45A7-8E2B-193E65BF564DQ73016481-0630F326-8E03-4747-ACEE-AFDF5974FF1CQ86210950-DE22C886-4DA0-4D58-822B-A35CE540EF20Q88373655-03E24A62-5E27-463C-AF85-F47106A9D777
P50
description
Japanese medical researcher
@en
wetenschapper
@nl
name
Sasaki T
@nl
Takashi Sasaki
@en
type
label
Sasaki T
@nl
Takashi Sasaki
@en
altLabel
Sasaki T
@en
prefLabel
Sasaki T
@nl
Takashi Sasaki
@en
P106
P31
P496
0000-0002-1413-6983